Kaposi's Sarcoma Clinical Trial
Official title:
The Seroprevalence of Kaposi's Sarcoma Herpesvirus in the United States
This study will investigate patterns of Kaposi's sarcoma herpes virus (KSHV) in the United
States and its potential impact on the U.S. population. KSHV is a newly discovered virus
that is strongly associated with Kaposi's sarcoma and primary effusion lymphoma. The high
prevalence of KS and KSHV among HIV-infected homosexual men suggests sexual contact as a
primary mode of transmission. Reports of non-sexual transmission in parts of Africa and the
Mediterranean where Kaposi's sarcoma is endemic, and the identification of viral DNA in
saliva and other bodily fluids, however, indicate the virus is also transmitted
non-sexually. This study will:
- Compare the prevalence of KSHV among different demographic groups in the United States
- Examine the association between KSHV and high risk behaviors such as drug use
(marijuana and cocaine), sexual behavior (age at first sexual intercourse and number of
sexual partners), and medical risk factors (herpes simplex virus II, hepatitis B and
hepatitis C)
- Estimate the prevalence of KSHV in the United States.
Data and blood samples for the study will be taken from the NHANES III survey. NHANES is a
program of periodic surveys conducted by the Centers for Disease Control and Prevention's
National Center for Health Statistics. The survey is designed to provide national estimates
of health status for the United States non-institutionalized civilian population by means of
household interviews, standardized physical examinations, and blood sample collection and
testing. NHANES III-the seventh in a series of national examination studies-was conducted
from 1988 to 1994.
This study will use the HANES data to identify risks associated with a KSHV-positive blood
test in the survey population. The study plans to include all 19,754 participants (67% of
the 29,314 participants originally examined) for whom blood samples were collected and
remain available.
Kaposi sarcoma herpesvirus (KSHV) is the viral cause of Kaposi sarcoma. Although infection with this virus appears to be uncommon in the United States, the prevalence in the general population in uncertain, and routes for transmission are poorly characterized. This study makes use of questionnaire data and serum specimens obtained in the third National Health and Nutrition Survey (NHAnes III). Sera from 18,168 individuals in this study were tested for antibodies to the KSHV proteins K8.1 and LANA. We will use these measurements to estimate KSHV seroprevalence for the overall U.S. general population and for demographic subgroups. To characterize potential transmission routes, we will also examine whether KSHV seroprevalence is related to sexual activity and exposures to blood, as indicated by responses to questionnaire items and previous NHANES III measurements of markers of relevant viral infections. ;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02201420 -
Evaluation of Technetium Tc 99m Tilmanocept (Lymphoseek®) Localization, Retention, and Distribution in Primary Cutaneous Kaposi's Sarcoma (KS) and Lymphatic Drainage From KS Lesions by SPECT and SPECT/CT Imaging
|
Phase 2 | |
Terminated |
NCT00686842 -
PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma
|
Phase 1/Phase 2 | |
Completed |
NCT00339326 -
Risk Factors for Non-HIV-Related Kaposi s Sarcoma
|
||
Completed |
NCT01352117 -
Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma
|
Phase 3 | |
Completed |
NCT01276236 -
Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)
|
Phase 2 | |
Completed |
NCT00001535 -
Twins Study of Gene Therapy for HIV Infection
|
Phase 1 | |
Completed |
NCT01067690 -
Treatment With Indinavir and Chemotherapy for Advanced Classical Kaposi's Sarcoma
|
Phase 2 | |
Completed |
NCT00540566 -
Optical Biopsy of Human Skin in Conjunction With Laser Treatment
|
||
Completed |
NCT00380770 -
HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT
|
Phase 4 | |
Completed |
NCT00001294 -
Genetic Factors and Interrelationships for Sexual Orientation, Susceptibility to HIV and Kaposi's Sarcoma, Alcoholism and Psychological Traits, and Histocompatibility Antigens
|
N/A | |
Completed |
NCT00055237 -
Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients
|
Phase 2 | |
Terminated |
NCT00287495 -
BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's Sarcoma
|
Phase 1 | |
Completed |
NCT00581815 -
Spectroscopy With Surface Coils and Decoupling
|
Phase 1 | |
Recruiting |
NCT00006518 -
Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
|
||
Completed |
NCT00001560 -
Clinical, Laboratory and Epidemiologic Pilot Studies of Individuals at High Risk for Viral-Associated Cancers
|
N/A | |
Completed |
NCT00982449 -
124I-FIAU Imaging in EBV and KSHV Associated Cancers
|
N/A | |
Recruiting |
NCT03300830 -
Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease
|
||
Completed |
NCT00006171 -
Effects of Potent Antiretroviral Therapy on Kaposi s Sarcoma
|
||
Completed |
NCT02029430 -
A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma
|
Phase 2 | |
Completed |
NCT00026793 -
Assessment of Blood Vessel Density in Kaposi's Sarcoma Lesions
|